IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

Metformin in the Management of Type 2 Diabetes Mellitus: Past, Present, and Future

Kandalkar Namrata Bhau*, Pawar Jayashree.R[1], Rohile Pratiksha.V[2], Divate Ashok R[3], Dr. Kuldeep P. Waidya[4]
[*1,2,] Students, Bachelor of Pharmacy
[3,] Assistant Professor, Bachelor of Pharmacy
Sahakar Maharshi Kisanravo Varal Patil College of Pharmacy, Nighoj, Maharashtra India

Abstract: *Metformin has been the cornerstone of type 2 diabetes mellitus (T2DM) management for over six decades. This biguanide medication has demonstrated remarkable efficacy, safety, and cost-effectiveness, maintaining its position as the first-line pharmacological therapy for T2DM worldwide. This comprehensive review examines the historical development of metformin, its mechanisms of action, current clinical applications, safety profile, and emerging therapeutic possibilities. We explore metformin's journey from botanical origins to modern medicine, its pleiotropic effects beyond glycemic control, and potential future applications in various disease states. Understanding metformin's multifaceted pharmacology provides insights into optimizing diabetes care and developing novel therapeutic strategies.*

Keywords*:* Metformin, Type 2 Diabetes, Biguanide, Glucose Metabolism, Cardiovascular Protection, AMPK

I. INTRODUCTION

Type 2 diabetes mellitus represents one of the most pressing global health challenges of the 21st century, affecting over 537 million adults worldwide as of 2021, with projections suggesting this number will exceed 783 million by 2045. The disease is characterized by insulin resistance and progressive β-cell dysfunction, leading to chronic hyperglycemia and its associated microvascular and macrovascular complications. Despite the proliferation of novel antidiabetic agents in recent decades, metformin remains the most prescribed medication for T2DM globally, with an estimated 150 million users worldwide.

The enduring success of metformin is remarkable considering its origins predate modern pharmaceutical development. Derived from the French lilac (Galega officinalis), metformin's journey from folk medicine to evidence-based therapy spans centuries. Its unique pharmacological profile, combining efficacy with safety and tolerability, has secured its position in all major diabetes management guidelines. Furthermore, accumulating evidence suggests metformin possesses therapeutic potential extending far beyond glycemic control, including cardiovascular protection, cancer prevention, anti-aging effects, and neuroprotection.

This review provides a comprehensive analysis of metformin's evolution, molecular mechanisms, clinical applications, safety considerations, and future therapeutic possibilities, offering insights into why this decadesold medication remains indispensable in modern diabetes care.

II. HISTORICAL PERSPECTIVE

2.1 Botanical Origins and Early History

The story of metformin begins in medieval Europe, where Galega officinalis (French lilac, goat's rue) was used in traditional medicine to relieve symptoms consistent with diabetes mellitus. The plant's glucose-lowering properties were attributed to its high content of guanidine, a compound later identified as having potent hypoglycemic effects. However, guanidine proved too toxic for clinical use, spurring the synthesis of derivative compounds with improved safety profiles.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

2.2 Development of Biguanides

In the 1920s, scientists synthesized biguanides—compounds containing two linked guanidine groups—as potential antimalarial agents. During these investigations, researchers Werner and Bell serendipitously discovered the glucose-lowering properties of these compounds. In 1929, Slotta and Tschesche demonstrated that biguanides could reduce blood glucose levels, but the advent of insulin therapy overshadowed this discovery.

Interest in biguanides resurfaced in the 1950s when French diabetologist Jean Sterne synthesized dimethylbiguanide (metformin) and introduced it for clinical use in 1957 under the trade name Glucophage, meaning "glucose eater." During this same period, other biguanides including phenformin and buformin were also developed and marketed.

2.3 The Rise and Fall of Biguanides

The 1970s witnessed a significant setback for biguanide therapy when phenformin was withdrawn from most markets due to its association with fatal lactic acidosis, with an incidence of approximately 40-64 cases per 100,000 patient-years. Buformin was similarly discontinued. These events cast a shadow over the entire biguanide class, and metformin's use remained limited primarily to Europe and Canada for the next two decades.

2.4 Renaissance and Global Acceptance

Metformin's global renaissance began with the landmark United Kingdom Prospective Diabetes Study (UKPDS), initiated in 1977. The study's results, published in 1998, demonstrated that metformin not only effectively controlled blood glucose but also reduced the risk of diabetes-related endpoints by 32% and allcause mortality by 36% in overweight patients compared to conventional treatment. Critically, metformin showed no increased risk of lactic acidosis compared to other treatments.

Following the UKPDS findings, the U.S. Food and Drug Administration approved metformin in 1995, marking its entry into the American market. Subsequently, major diabetes organizations, including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), established metformin as the first-line pharmacological therapy for T2DM, a recommendation that persists in current guidelines.

III. PHARMACOLOGY AND MECHANISMS OF ACTION

3.1 Pharmacokinetics

Metformin exhibits unique pharmacokinetic properties that distinguish it from most oral medications. Following oral administration, metformin is absorbed primarily in the small intestine, with bioavailability ranging from 5060% under fasting conditions. Food decreases and delays absorption but does not significantly affect the extent of absorption. The drug reaches peak plasma concentrations within 2-3 hours for immediate-release formulations and 4-8 hours for extended-release preparations.

Metformin is not bound to plasma proteins and does not undergo hepatic metabolism, being excreted unchanged in the urine via active tubular secretion. The plasma elimination half-life is approximately 4-9 hours, while the elimination half-life from blood is approximately 17.6 hours, suggesting erythrocyte accumulation. Steady-state concentrations are achieved within 24-48 hours with conventional dosing regimens.

The drug's cellular uptake and distribution are mediated by organic cation transporters (OCTs), particularly OCT1 in hepatocytes and OCT2 in renal tubular cells. Genetic polymorphisms in OCT1 can influence metformin's pharmacokinetics and pharmacodynamics, potentially explaining inter-individual variability in treatment response.

3.2 Molecular Mechanisms

Being a drug that can act on various organ system and have varied effects, the mechanism of action of metformin tends to be diverse and are based on the indication of the drug. This section elaborates on the mechanism of action of metformin under various potential uses (Figure 1).

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

Table 1 Summary of the Pharmacokinetics Characteristics of Metformin

Pharmacokinetics Parameters	Values
Absolute bioavailability	50–60% in healthy individuals
Time to reach Cmax (Tmax)	2.5 hours
Kinetics of metformin absorption	Non-linear
At scheduled and recommended doses time to reach steady state plasma concentration	24–48 hours
Steady state plasma concentration	Less than 1 μg/mL
Mean volume of distribution (Vd)	Ranged between 63–276 L
Selective distribution	Red blood cells most likely represent a secondary compartment of distribution
Excretion	Unchanged in urine
Renal clearance	>400mL/min (indicating glomerular filtration and tubular secretion
Apparent terminal elimination half-life	Approximately 6.5 hours

Note: Data from [8,15]



Figure 1 :- Actions of Metformin.

3.3 Glucose Metabolism

Metformin is primarily recognized as a glucose-lowering agent and is established as a monotherapy and combination therapy with other "anti-diabetic" drugs as a first-line therapy conventionally. Metformin being a hydrophilic molecule has also been observed to have metal-binding properties, principally with copper.Metformin's hydrophilic nature makes it arduous to cross the cell membrane and hence it depends on the membrane transporters like hENT4 ("human equilibrative nucleoside transporter 4"), MATE ('Multidrug and Toxin Extrusion Protein'), and SLC22A (Solute Carrier Family 22 members) for its uptake into the cell and secretion.19 SLC22A gene family is further subdivided into

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

several subgroups and OCTs ('Organic Cation Transporters') like OCT1, OCT2, and OCT3 are also a part of it and are coded by genes namely SLC22A1, SLC22A2, and SLC22A3, respectively, which are clustered on chromosome 6q26-q27 and share a structure with 11 coding exons and 10 introns.These OCT transporters are responsible for the transport of drugs and other molecules across the drug absorption, metabolism, and excretion in the small intestine, liver, and kidney. Metformin has been found to be a substrate of OCT3 present in the brush border membrane of the enterocytes.

Conventionally, it is quite established that metformin lowers blood glucose primarily by its action on the liver with a major effect by minimizing hepatic gluconeogenesis leading to curtailment in endogenous glucose production by the liver without a concomitant increase in plasma insulin concentrations.Literature reveals that gluconeogenesis is responsible for about 28–97% of total hepatic glucose output which in turn further depends on the feeding status in the case of normal persons and can be higher in patients with chronic T2D. In cases of T2D, which is a chronic condition, this mechanism can be crucial as enhanced and unregulated hepatic glucose release is a prominent pathophysiological mechanism, and controlling it can improve the prognosis of the disease to a large extent.

The high expression of SLC22A1 in the liver and high concentration of metformin in portal circulation as compared to other parts of the body aids in its enhanced action on liver gluconeogenesis pathways.Evidence shows that metformin enhances the activity of IRS-2 ("Insulin Receptor Substrate 2") in the cells and translocates the glucose transporters like Glucose transporter (GLUT)-1 to boost glucose uptake by the cells.

At the cellular level, metformin was thought to primarily act on the mitochondrion and has an ephemeral inhibitory action on the complex I of the electron transport chain of mitochondria culminating to a dip in the energy level of the cell. Though recent evidence does not favor metformin's effect on complex I because the concentration needed to inhibit it is way higher than what is observed in the clinical use of this drug. In support of this, a complex I inhibitor piericidin was pumped into rat livers via an indwelling portal venous catheter, and the procedure showed that piericidin does not suppress hepatic gluconeogenesis.This decline in the energy level which is directly correlated with diminished synthesis of ATP ("Adenosine Triphosphate") and enhanced AMP ("Adenosine monophosphate") levels could be the driving force for crucial processes in the liver such as blocking cAMP ("cyclic AMP") generation induced by glucagon and the activating 5'- AMPK ("Adenosine Monophosphate-Activated Protein Kinase").The same concept is also evident from the preclinical studies on isolated hepatocytes of rats where metformin was observed to reduce ATP concentration in the mitochondria. ATP is known to allosterically block the enzyme pyruvate kinase and hence a reduction in ATP concentration leads to enhanced pyruvate kinase activity and decreased glucose output.

Metformin was also found to activate AMPK intracellularly which acts as a sensor of energy in the cell and it is observed that on activation of AMPK, the catabolic processes of the cells get triggered and lead to the generation of ATP whereas disabling the anabolic pathways using ATP for synthetic processes. Evidence shows AMPK is a crucial facilitator for complex intracellular molecular signaling pathways of metabolism and growth which act in an integrated manner to ensure a balance of cellular energy (Figure 2).

The decline in energy levels by diminished synthesis of ATP and resultant enhanced levels of AMP by increased activity of enzyme adenylate kinase is observed. Evidence shows that metformin can even elevate AMP levels by blocking the activity of an enzyme named AMP deaminase that breaks down AMP. Metformin, by elevating levels of intracellular AMP levels, might block adenylate cyclase, which facilitates the conversion of ATP to cAMP, hence reducing intracellular cAMP levels and ultimately reducing the signalling of glucagon, leading to reduced glucose levels.The above effect of reduced glucose output by gluconeogenesis through activation of AMPK is also supported by the fact that 5- AICAR ("aminoimidazole-4-carboxamide riboside"), which is an AMPK activating molecule has also shown the evident effect of diminished enzymes expression involved in gluconeogenesis, hence leading to decreased glucose output as seen in preclinical trials.The effect of metformin is also supported by a study done by Shaw et al on mice given a high-fat diet, where deletion of gene LKB1 ("Liver Kinase B1"), which is a crucial enzyme phosphorylating the catalytic α AMPK domain led to the deactivation of AMPK leading to elevated glucose levels, hence nullifying the glucose reducing metformin effect.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67



Figure 2 Beneficial effects of metformin.

These mechanisms have been thought to explain metformin's action, but recent evidence reveals that the action of metformin can be otherwise. Schäfer et al reported that the binding affinity of metformin for mitochondrial membranes is modest and Wilcock et al observed that the distribution of metformin is majorly in the cytosol and only less than 10% enters mitochondria.Meng et al, in their study on mouse-isolated hepatocytes, reported that a low concentration of metformin (25–100 μM) activated AMPK, whereas a higher concentration (500 μM) inhibited it.Ravera et al studied the concentration- dependent metabolic effect of metformin and reported that low concentration (15–150 μM), which represents the clinical levels of the drug triggered oxidative phosphorylation, the oxidative stress response, and the AMPK/Sirt1 pathway, whereas 1.5 mM was hazardous.Metformin's antihyperglycemic impact via the reduction of hepatic gluconeogenesis was first revealed by Zhou et al and they observed that it activated AMPK in rat hepatocytes at doses of 10 μM and 20 μM and provided a cellular basis for the drug's blood glucose lowering action.Cao et al demonstrated that modest dosages of metformin decreases glucose synthesis in primary hepatocytes without altering levels of ATP or the AMP/ATP ratio. A study by Miller et al on hepatocytes demonstrated that a cessation of glucose production in primary hepatocytes was achieved at 125 μM, and it needed a higher concentration of 250 μM to considerably reduced cellular cAMP levels and much lower plasma levels are also efficient at reducing the synthesis of glucose by hepatocytes.

IV. CLINICAL EFFICACY IN TYPE 2 DIABETES

4.1 Glycemic Control

Metformin typically reduces glycated hemoglobin (HbA1c) by 1.0-1.5% when used as monotherapy in treatment-naive patients. This effect is dose-dependent, with maximal efficacy achieved at doses of 2000-2550 mg daily. Unlike sulfonylureas and insulin, metformin does not cause hypoglycemia when used alone, as it does not increase insulin secretion but rather enhances insulin sensitivity.

The glucose-lowering effect of metformin is sustained over time, with studies demonstrating maintenance of glycemic control for several years. The UKPDS demonstrated that metformin preserved β-cell function better than sulfonylureas or insulin, with slower progression to treatment failure.

4.2 Weight Effects

A distinctive advantage of metformin is its weight-neutral to modest weight-reducing effect, contrasting with the weight gain associated with sulfonylureas, thiazolidinediones, and insulin. Patients typically experience weight loss of 1-3 kg

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

during the first year of treatment, which persists with continued therapy. This property is particularly valuable in T2DM, where obesity is a predominant feature and weight loss improves insulin sensitivity and cardiovascular risk factors.

The mechanisms underlying metformin's weight effects include reduced appetite (possibly mediated by increased GLP-1 secretion), decreased intestinal glucose absorption, and increased fat oxidation. These effects make metformin an attractive option for overweight and obese patients with T2DM.

4.3 Cardiovascular Outcomes

The UKPDS provided landmark evidence for metformin's cardiovascular benefits, demonstrating a 39% reduction in myocardial infarction and a 36% reduction in all-cause mortality in overweight patients compared to conventional treatment. These benefits exceeded those expected from glycemic control alone, suggesting direct cardiovascular protective effects.

Subsequent studies have confirmed metformin's cardiovascular safety, if not benefit. Proposed mechanisms for cardioprotection include:

- Improvement in endothelial function
- Reduction in oxidative stress and inflammation
- Favorable effects on lipid profile
- Antiplatelet and antithrombotic effects
- Reduction in advanced glycation end products
- Direct myocardial protection through AMPK activation

Meta-analyses have consistently shown that metformin is associated with reduced cardiovascular events and mortality compared to other glucose-lowering agents. Current guidelines recognize metformin's established cardiovascular safety, though newer agents (SGLT2 inhibitors and GLP-1 receptor agonists) have demonstrated more robust cardiovascular outcome benefits in dedicated trials.

4.4 Combination Therapy

Metformin serves as the foundation for combination therapy with other antidiabetic agents. It can be effectively combined with:

- Sulfonylureas: Complementary mechanisms provide additive glycemic control
- DPP-4 inhibitors: Enhanced incretin effects with improved tolerability
- GLP-1 receptor agonists: Synergistic glucose-lowering with additional weight loss
- SGLT2 inhibitors: Complementary mechanisms with cardiovascular and renal benefits
- Thiazolidinediones: Improved insulin sensitivity through different pathways
- Insulin: Reduced insulin requirements and weight gain mitigation

Current treatment algorithms recommend continuing metformin throughout the disease course, adding other agents as needed to achieve glycemic targets, unless contraindicated or not tolerated.

V. SAFETY PROFILE AND ADVERSE EFFECTS

5.1 Gastrointestinal Adverse Effects

The most common adverse effects of metformin are gastrointestinal, occurring in 20-30% of patients. These include diarrhea, nausea, vomiting, flatulence, abdominal discomfort, and metallic taste. These symptoms are typically transient, occurring early in treatment and resolving within weeks as tolerance develops.

Strategies to minimize gastrointestinal adverse effects include:

- Initiating therapy with low doses (500 mg once or twice daily)
- Gradual dose titration over several weeks
- Taking medication with meals
- Using extended-release formulations, which have better tolerability

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

- Temporary dose reduction followed by re-titration

Approximately 5% of patients cannot tolerate metformin due to persistent gastrointestinal symptoms, necessitating discontinuation.

5.2 Lactic Acidosis

Lactic acidosis is the most serious potential adverse effect of metformin, though its actual incidence is extremely low (approximately 3-10 cases per 100,000 patient-years), similar to the background rate in diabetic populations not taking metformin. Most reported cases occur in patients with contraindications to metformin use, particularly renal impairment.

Metformin-associated lactic acidosis (MALA) results from impaired metformin clearance leading to drug accumulation, increased lactate production (particularly from the intestine), and possibly impaired hepatic lactate clearance. Risk factors include:

- Severe renal impairment
- Acute kidney injury
- Hepatic dysfunction
- Severe hypoxemia or hypoperfusion
- Sepsis
- Acute heart failure
- Recent myocardial infarction
- Heavy alcohol use

Current guidelines recommend careful patient selection, regular monitoring of renal function, and temporary discontinuation during acute illnesses or procedures involving contrast agents.

5.3 Vitamin B12 Deficiency

Long-term metformin use is associated with reduced vitamin B12 absorption, affecting 10-30% of users after several years of treatment. The mechanism involves interference with calcium-dependent B12-intrinsic factor absorption in the terminal ileum. Risk factors for B12 deficiency include longer duration of use, higher doses, and older age.

Vitamin B12 deficiency can cause megaloblastic anemia, neuropathy, cognitive impairment, and hyperhomocysteinemia. Current recommendations include periodic monitoring of B12 levels (every 2-3 years or if symptoms develop) and supplementation when deficiency is detected. Some experts advocate for routine supplementation in all long-term metformin users.

5.4 Renal Considerations

Historically, metformin was contraindicated in patients with any degree of renal impairment due to concerns about lactic acidosis. However, accumulating evidence demonstrating metformin's safety in mild to moderate renal impairment led to revised recommendations.

Current FDA guidelines (updated in 2016) recommend:

- eGFR $\geqslant$60 mL/min/1.73m^2 : No dosage adjustment necessary eGFR 45-59:
- May continue current dose; do not initiate treatment eGFR 30-44:
- Maximum dose 1000 mg daily; monitor renal function every 3-6 months eGFR <30:
- Contraindicated

These liberalized recommendations expand metformin's use to many patients previously denied this effective therapy, while maintaining appropriate safety precautions.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

5.5 Other Considerations

Contrast-Induced Nephropathy: Traditional recommendations called for metformin discontinuation before iodinated contrast procedures. Updated guidelines suggest continuation is safe in patients with eGFR ⩾60, with renal function assessment 48 hours post-procedure for those with eGFR 45-59.

Surgical Procedures: Metformin should be withheld on the day of surgery involving general anesthesia and resumed when renal function is stable and oral intake restored.

Pregnancy: Metformin crosses the placenta but has been used extensively in polycystic ovary syndrome and gestational diabetes with apparent safety. However, insulin remains the preferred treatment for diabetes in pregnancy in most guidelines.

VI. CURRENT CLINICAL PRACTICE AND GUIDELINES

6.1 First-Line Therapy Recommendation

All major diabetes organizations, including the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), International Diabetes Federation (IDF), and National Institute for Health and Care Excellence (NICE), recommend metformin as the first-line pharmacological therapy for T2DM, alongside lifestyle modifications.

The rationale for this recommendation includes:

- Proven efficacy in glycemic control
- Low risk of hypoglycemia
- Weight-neutral or weight-reducing effect
- Established cardiovascular safety with potential benefit
- Extensive safety record over six decades
- Low cost and global availability
- Beneficial effects on multiple metabolic pathways

6.2 Patient-Centered Approach

Modern diabetes management emphasizes individualized treatment plans considering patient characteristics, preferences, comorbidities, and therapeutic goals. While metformin remains the foundation, certain clinical scenarios may warrant alternative or additional first-line agents:

Established cardiovascular disease or high cardiovascular risk: Consider early addition of SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefits.

Chronic kidney disease: SGLT2 inhibitors may be preferred given their renal protective effects, though metformin can be continued with dose adjustment based on eGFR.

Heart failure: SGLT2 inhibitors have demonstrated benefits in reducing heart failure hospitalizations.

Overweight/obesity: GLP-1 receptor agonists may be preferred for their substantial weight loss effects, though metformin's modest weight-reducing effect remains valuable.

Significant hyperglycemia: Early combination therapy or insulin may be necessary, though metformin should be included if not contraindicated.

6.3 Dosing Strategies

Immediate-Release Formulations:

- Starting dose: 500 mg once or twice daily with meals
- Titration: Increase by 500 mg weekly or 850 mg every 2 weeks as tolerated
- Target dose: 2000 mg daily (1000 mg twice daily)
- Maximum dose: 2550 mg daily (850 mg three times daily)

Extended-Release Formulations:

- Starting dose: 500 mg once daily with evening meal

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

- Titration: Increase by 500 mg weekly as tolerated
- Target dose: 2000 mg once daily
- Maximum dose: 2000 mg once daily

Extended-release formulations improve tolerability and may enhance adherence but are more expensive than immediate-release preparations.

6.4 Monitoring Requirements

Renal function: At baseline, at least annually, and more frequently if eGFR <60 or other risk factors present

VII. SPECIAL POPULATIONS

7.1 Prediabetes and Diabetes Prevention

The Diabetes Prevention Program (DPP) demonstrated that metformin reduced the incidence of T2DM by 31% over 2.8 years in individuals with prediabetes, though lifestyle intervention was more effective (58% reduction). Metformin's preventive effect was most pronounced in younger individuals (<45 years) and those with higher BMI ($\geqslant$35 kg/m^2).

Long-term follow-up of DPP participants showed sustained diabetes risk reduction with metformin over 15 years. Based on this evidence, the ADA recommends considering metformin for diabetes prevention in individuals with prediabetes, particularly those aged <60 years, with BMI $\geqslant$35 kg/m^2 , and women with prior gestational diabetes.

7.2 Polycystic Ovary Syndrome (PCOS)

Metformin has been used extensively in PCOS management, despite not being FDA-approved for this indication. In PCOS, metformin improves insulin sensitivity, reduces androgen levels, promotes ovulation, and may improve metabolic parameters. It is commonly used alone or combined with clomiphene citrate for ovulation induction in women seeking fertility.

However, evidence for metformin's effectiveness in improving pregnancy outcomes and reducing long-term complications in PCOS remains mixed. Current guidelines suggest metformin as an adjunct to lifestyle modification in PCOS patients with insulin resistance or impaired glucose tolerance.

7.3 Pediatric Population

Metformin is FDA-approved for use in children aged $\geqslant$10 years with T2DM. The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study demonstrated that metformin effectively controls glycemia in pediatric T2DM, though combination therapy or insulin is often required. The safety profile in children appears similar to adults, with gastrointestinal adverse effects being most common.

Metformin is increasingly used off-label in pediatric obesity management and PCOS, with growing evidence supporting its safety and modest efficacy in these conditions.

7.4 Elderly Patients

Metformin is generally well-tolerated in older adults with T2DM and remains first-line therapy when appropriate. However, special considerations include:

- Higher prevalence of renal impairment requiring dose adjustment
- Increased risk of vitamin B12 deficiency
- Greater sensitivity to gastrointestinal adverse effects
- Multiple comorbidities and polypharmacy
- Need for less stringent glycemic targets to minimize hypoglycemia risk

Careful patient selection, appropriate dosing based on renal function, and regular monitoring are essential for safe metformin use in elderly populations.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

7.5 Gestational Diabetes and Pregnancy

While insulin has traditionally been the standard treatment for gestational diabetes, metformin has been increasingly studied and used in this setting. The MiG (Metformin in Gestational Diabetes) trial demonstrated that metformin was effective and safe for managing gestational diabetes, with some women requiring supplemental insulin.

Concerns exist regarding metformin's placental transfer and potential long-term effects on offspring. Follow-up studies of children exposed to metformin in utero have generally shown reassuring results, though longer-term data are needed. Current guidelines vary, with some accepting metformin as an alternative to insulin in gestational diabetes, while others maintain insulin as preferred therapy.

VIII. THERAPEUTIC USES OF METFORMIN

8.1 Metformin and Diabetes

Metformin gained the status of “foundation therapy” in T2D patients whose glycemic target is not achieved despite diet and other lifestyle interventions. The reason behind this glory is its effective glycemic control, weight neutrality, wide security margin, and low cost. In addition to the mentioned benefits, metformin also provides modest cardioprotection and improvement in various lipids and inflammatory marker profiles. Metformin’s mechanism of action is complex and is yet to be completely understood. Metformin primarily acts by reducing glucose production by inhibiting AMPK-dependent gluconeogenic enzymes in the liver, yet not all its impacts are described by its mechanism.It has been found that metformin also acts on the gut and increases glucose utilization and GLP-1 production in addition to alteration in the microbiome population.



Figure 3 :- Neuroprotective role of metformin.

Metformin alone and in combination with other “glucose-lowering” agents reduce the blood glucose level effectively in T2D.It was found that combinations of metformin with all noninsulin diabetic drugs result in a similar reduction of HbA1c but with changing weight gain degrees and hypoglycemia risk. In addition to glucose control, metformin is also helpful in diabetes-related comorbidities. Diabetes has been regarded as a risk factor for coronary artery illness. UKPDS (“UK Prospective Diabetes Study”), a large randomized clinical study in the newly diagnosed T2D population found significant as well as persistent risk reduction in myocardial infarction (33%, $p = 0.005$), death from any cause (27%, $p = 0.002$) and diabetes-related endpoint (21%, $p = 0.01$) in metformin-treated individuals.Obesity and diabetes are interrelated. Metformin has a neutral influence on body weight in patients with T2D. It is associated with a reduction in weight gain when compared with sulfonylureas, thiazolidinediones, and insulin. Metformin contributes to weight loss by reducing intestinal carbohydrate absorption and insulin resistance in addition to reducing ghrelin and

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

leptin levels. Different forms of cancers like rectum, pancreas, liver, and colon are observed to have a high incidence in T2D. The high occurrence of tumorigenesis is related to hyperinsulinemia, insulin resistance, elevated level of IGF-1, and hyperglycemia. Metformin being an insulin sensitizer reduces insulin resistance and hyperinsulinemia. AMPK activation, mTOR pathway inhibition; angiogenesis, and inflammation are the other suggestive mechanisms of metformin's action. The usual starting metformin dose is 500mg every day with an evening meal and if required can add an additional 500 mg dose with breakfast. The dose of metformin is titrated gradually and can reach a maximum dose of 2000 mg per day; however, the dose of metformin can vary depending on the other factors including body mass index. The role of metformin in pregnant females with diabetes is controversial. A meta-analysis conducted on observational studies did not reveal a rise in neonatal deaths or congenital malformations in women taking metformin alone or in a mixture with sulfonylureas while MiG (metformin in gestational) trials suggest more incidence of preterm birth and less weight gain in women taking metformin as compared to those who were on insulin. After the MiG trial, metformin's utility has increased in pregnancy. Metformin easily crosses the placenta and maintains a concentration in the blood of the foetus that is nearly half to as concentrated as it is in the mother's plasma. There are worries about the use of metformin during pregnancy since it has anti-cell growth and pro-apoptotic effects that could harm the developing baby. Therefore, more human studies are needed to assess the safety of metformin in pregnancy.

Recently, metformin has been hypothesized to be used as an adjunct treatment in type 1 diabetes to limit the insulin dose and to prevent the long-term difficulties of diabetes including weight gain, atherosclerotic progression, as well as elevated cholesterol levels of LDL. REMOVAL ("Reducing with Metformin Vascular Adverse Lesions") trial which is one of the longest and largest trials of metformin treatment within type 1 diabetes patients reported a small but sustained reduction in LDL cholesterol and weight in middle-aged adults over 3 years. The trial also suggested the role of metformin in cardiovascular risk reduction instead of sustained glucose-reducing effect in type 1 diabetes. However, metformin may minimize weight gain, and somewhat improve cholesterol levels but does not lower HbA1c levels in type 1 diabetes. Yet again, this comes with a higher risk of unfavorable gastrointestinal side effects and vitamin B12 shortage. Given the ambiguity around the potential long-term advantages, it is thought that metformin has very little part to play in the treatment of type 1 diabetes.

IX. DRUG INTERACTIONS AND CONTRAINDICATIONS

9.1 Significant Drug Interactions

Cationic drugs: Medications that compete for renal tubular secretion (e.g., cimetidine, ranitidine, amiloride, digoxin, morphine, trimethoprim) may increase metformin levels and risk of adverse effects.

Carbonic anhydrase inhibitors: Topiramate and zonisamide may increase lactic acidosis risk through additive effects on acid-base balance.

Alcohol: Acute or chronic excessive alcohol consumption increases lactic acidosis risk and should be avoided.

Contrast media: Iodinated contrast agents increase acute kidney injury risk; metformin management around procedures should follow current guidelines.

Drugs affecting glycemic control: Corticosteroids, thiazide diuretics, sympathomimetics, and thyroid hormones may worsen glycemic control, requiring metformin dose adjustment.

9.2 Contraindications

Absolute contraindications:

- Severe renal impairment (eGFR <30 mL/min/1.73m²)
- Metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to metformin
- Acute conditions with hypoxia or hypoperfusion risk

Relative contraindications (requiring careful assessment):

- Moderate renal impairment (eGFR 30-44 mL/min/1.73m2)—dose reduction required
- Hepatic impairment—impaired lactate clearance increases risk

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

- Excessive alcohol intake
- Congestive heart failure requiring pharmacologic management
- Acute myocardial infarction or stroke
- Sepsis

X. FUTURE DIRECTIONS AND NOVEL FORMULATIONS

10.1 Enhanced Formulations

Delayed-release metformin: A novel formulation delivering metformin to the lower bowel may enhance GI tolerability while maintaining efficacy by targeting mechanisms in the distal intestine.

Combination products: Fixed-dose combinations with other antidiabetic agents (DPP-4 inhibitors, SGLT2 inhibitors) improve adherence and simplify regimens.

Modified-release systems: Advanced drug delivery technologies aim to optimize metformin's pharmacokinetics and reduce dosing frequency.

10.2 Biomarker-Guided Therapy

Research into pharmacogenomics, particularly OCT1 polymorphisms, may enable personalized metformin dosing based on genetic variants affecting drug transport and efficacy. Additionally, biomarkers predicting treatment response could optimize patient selection.

10.3 Precision Medicine Approaches

Understanding metformin's complex mechanisms may enable targeting specific pathways for enhanced therapeutic effects. For example:

Developing agents that selectively activate AMPK

Enhancing metformin's gut-based mechanisms

Combining metformin with agents targeting complementary pathways

10.4 Expanding Indications

Ongoing clinical trials investigating metformin in cancer, aging, neurodegenerative diseases, and cardiovascular disease in non-diabetics may expand its therapeutic applications significantly. Success in these areas would establish metformin as one of medicine's most versatile medications.

10.5 Sustainability and Global Health

As generic metformin is widely available and inexpensive, ensuring access in low- and middle-income countries remains a priority. Metformin's favorable cost-effectiveness profile makes it particularly valuable in resource-limited settings. Additionally, environmental concerns regarding metformin's presence in water systems due to incomplete human metabolism require attention to minimize ecological impact.

XI. CHALLENGES AND CONTROVERSIES

11.1 Gastrointestinal Intolerance

The 5-10% of patients who cannot tolerate metformin due to persistent GI symptoms present a clinical challenge. Alternative formulations (extended-release, delayed-release) may help, but some patients remain intolerant. Research into predicting and preventing metformin intolerance could expand its use.

11.2 Vitamin B12 Deficiency

The optimal strategy for monitoring and preventing vitamin B12 deficiency in long-term metformin users remains debated. Questions include optimal screening intervals, whether routine supplementation should be recommended, and the clinical significance of subclinical deficiency.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, November 2025 Impact Factor: 7.67

11.3 Efficacy Variability

Substantial inter-individual variability in metformin response exists, with some patients achieving excellent glycemic control while others show minimal benefit. Identifying predictors of response (genetic, clinical, metabolic) could improve treatment personalization.

11.4 Optimal Dosing in Non-Diabetes Indications

If metformin finds expanded applications beyond diabetes, determining optimal dosing regimens for conditions like cancer prevention, anti-aging, or cardiovascular protection will be essential. Doses effective for glycemic control may not be optimal for other indications.

11.5 Environmental Impact

Metformin is detected in surface waters worldwide due to incomplete metabolism and wastewater treatment. While current concentrations appear below levels causing human health concerns, potential ecological effects require monitoring and mitigation strategies.

XII. CONCLUSION

Metformin's journey from botanical medicine to modern pharmaceutical cornerstone represents one of medicine's great success stories. Over six decades of clinical use have established its efficacy, safety, and costeffectiveness in managing T2DM, securing its position as first-line therapy in global guidelines. Beyond glycemic control, metformin's pleiotropic effects—including cardiovascular protection, weight neutrality, and absence of hypoglycemia—distinguish it from alternative agents.

The drug's remarkably low cost, global availability, and extensive safety record make it particularly valuable in addressing the diabetes pandemic, especially in resource-limited settings. While newer antidiabetic agents offer specific advantages for certain patient populations, metformin remains the foundation upon which most diabetes treatment regimens are built.

Perhaps most exciting is metformin's potential extending far beyond diabetes management. Accumulating evidence suggests roles in cancer prevention, cardiovascular disease, anti-aging, and various other conditions. If ongoing research confirms these benefits, metformin may become one of the most widely used preventive medications in history.

However, challenges remain, including managing intolerance, preventing vitamin B12 deficiency, understanding response variability, and determining optimal use in expanded indications. Future research employing precision medicine approaches, novel formulations, and biomarker-guided therapy may further optimize metformin's therapeutic utility.

As we look to the future, metformin exemplifies how thorough understanding of a drug's mechanisms can reveal unexpected therapeutic possibilities. Whether preventing diabetes, extending healthspan, or reducing cancer risk, this venerable medication continues to surprise and impress researchers and clinicians alike. The next decades will likely expand metformin's applications while maintaining its central role in diabetes care, ensuring this remarkable drug remains relevant and valuable for generations to come.

REFERENCES

[1]. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium: International Diabetes Federation; 2021.
[2]. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S19-S40.
[3]. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140-S157.
[4]. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579.
[5]. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

[6]. Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108(8):1105-1107.
[7]. Watanabe CK. Studies in the metabolic changes induced by administration of guanidine bases. J Biol Chem. 1918;33:253-265.
[8]. Sterne J. Du nouveau dans les antidiabétiques. La NN dimethylamine guanyl guanide (NNDG). Maroc Med. 1957;36:1295-1296.
[9]. Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int. 2004;21(3):115-117.
[10]. Luft D, Schmülling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia. 1978;14(2):75-87.
[11]. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854- 865.
[12]. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patientcentered approach. Diabetes Care. 2012;35(6):1364-1379.
[13]. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32(1):193-203.
[14]. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81-98.
[15]. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235-246.
[16]. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359-371.
[17]. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49(12):2063-2069.
[18]. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-1174.
[19]. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953-966.
[20]. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):541-549.
[21]. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198-205.
[22]. Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatmentnaive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850-858.
[23]. Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41(3):547-553.
[24]. Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res. 2014;7(9):867-885.
[25]. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065.
[26]. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668-2675.
[27]. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-613.
[28]. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
[29]. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157(9):601-610.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

[30]. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616-625.

[31]. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565-572.

[32]. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.

[33]. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-875.

[34]. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.

[35]. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003-2015.

[36]. de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.

[37]. Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014;16(11):1165-1173.

[38]. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065.

[39]. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426-435.

[40]. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967.

[41]. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.

[42]. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34(6):1431-1437.

[43]. Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med. 2017;166(3):191-200.

[44]. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885-904.

[45]. American College of Radiology. Manual on contrast media, version 10.3. Reston, VA: American College of Radiology; 2018.

[46]. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.

[47]. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab. 2011;37(2):90-96.

[48]. TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247-2256.

[49]. Dhatariya K, Levy N, Kilvert A, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabet Med. 2012;29(4):420-433.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, November 2025
Impact Factor: 7.67

[50]. Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58(6):1434-1439.

[51]. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198-205.

[52]. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2013;1(1):57-64.

[53]. Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev. 2017;40:31-44.

[54]. Bouitbir J, Charles AL, Echaniz-Laguna A, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. Eur Heart J. 2012;33(11):1397-1407.

[55]. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care. 2003;26(1):138-143.

[56]. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316(3):313- 324.

[57]. World Health Organization. WHO Model List of Essential Medicines, 22nd List. Geneva: World Health Organization; 2021.

[58]. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33(8):1859-1864.

[59]. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.

[60]. Giugliano D, Maiorino MI, Bellastella G, Esposito K. Type 2 diabetes and cardiovascular prevention: the dogmas disputed. Endocrine. 2018;60(2):224-228.

[61]. International Diabetes Federation. IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care. Brussels: International Diabetes Federation; 2017.

[62]. Scheurer M, Michel A, Brauch HJ, Ruck W, Sacher F. Occurrence and fate of the antidiabetic drug metformin and its metabolite guanylurea in the environment and during drinking water treatment. Water Res. 2012;46(15):4790-4802.

[63]. Niemuth NJ, Klaper RD. Emerging wastewater contaminant metformin causes intersex and reduced fecundity in fish. Chemosphere. 2015;135:38-45